Multifunctional enkephalin analogs with a new biological profile: Mor/dor agonism and kor antagonism
Name:
biomedicines-09-00625-v3.pdf
Size:
2.992Mb
Format:
PDF
Description:
Final Published Version
Author
Lee, Y.S.Remesic, M.
Ramos-Colon, C.
Wu, Z.
Lavigne, J.
Molnar, G.
Tymecka, D.
Misicka, A.
Streicher, J.M.
Hruby, V.J.
Porreca, F.
Affiliation
Department of Pharmacology, University of ArizonaDepartment of Chemistry and Biochemistry, University of Arizona
Issue Date
2021Keywords
Analgesic effectsKappa receptor antagonists
Multifunctional activity
Opioid receptors
Peptidomimetics
Plasma stability
Template-based alignment modeling
Metadata
Show full item recordPublisher
MDPI AGCitation
Lee, Y. S., Remesic, M., Ramos-Colon, C., Wu, Z., Lavigne, J., Molnar, G., Tymecka, D., Misicka, A., Streicher, J. M., Hruby, V. J., & Porreca, F. (2021). Multifunctional enkephalin analogs with a new biological profile: Mor/dor agonism and kor antagonism. Biomedicines, 9(6).Journal
BiomedicinesRights
Copyright © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).Collection Information
This item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at repository@u.library.arizona.edu.Abstract
In our previous studies, we developed a series of mixed MOR/DOR agonists that are enkephalin-like tetrapeptide analogs with an N-phenyl-N-piperidin-4-ylpropionamide (Ppp) moiety at the C-terminus. Further SAR study on the analogs, initiated by the findings from off-target screening, resulted in the discovery of LYS744 (6, Dmt-DNle-Gly-Phe(p-Cl)-Ppp), a multifunctional ligand with MOR/DOR agonist and KOR antagonist activity (GTPS assay: IC50 = 52 nM, Imax = 122% cf. IC50 = 59 nM, Imax = 100% for naloxone) with nanomolar range of binding affinity (Ki = 1.3 nM cf.Ki = 2.4 nM for salvinorin A). Based on its unique biological profile, 6 is considered to possess high therapeutic potential for the treatment of chronic pain by modulating pathological KOR activation while retaining analgesic efficacy attributed to its MOR/DOR agonist activity. © 2021 by the authors. Licensee MDPI, Basel, Switzerland.Note
Open access journalISSN
2227-9059Version
Final published versionae974a485f413a2113503eed53cd6c53
10.3390/biomedicines9060625
Scopus Count
Collections
Except where otherwise noted, this item's license is described as Copyright © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).